AI Investor Forum: Gus Tai on AI in Healthcare (Part 2)

Sramana Mitra: Google’s AlphaFold is a good example of a model. A lot of scientists have been given access to it at an affordable price point. The impact it is having on scientific discovery and research is humongous. Somewhere in this continuum, I see that there’s a missing area where there is no Platform as a Service (PaaS) like AlphaFold that scientists can tap into to do drug discovery work using AI.

AI Investor Forum: Gus Tai on AI in Healthcare (Part 1)

Gus Tai, Investor, Board Member and Retired General Partner at Trinity Ventures, discusses AI in Healthcare startups. Fascinating, comprehensive discussion with concrete pointers.

666th 1Mby1M Entrepreneurship Podcast with Investor Gus Tai (Part 3, 2024)

Gus Tai, Investor, Board Member and Retired General Partner at Trinity Ventures, discusses AI in Healthcare startups. Fascinating, comprehensive discussion with concrete pointers.

Podcast: Play in new window | Download

Subscribe: Apple Podcasts | Android | Google Play | Stitcher | TuneIn | RSS

Scaling to $500M in Revenue: ModMed CEO Daniel Cane (Part 7)

Sramana Mitra: In a fifteen-year span, the early venture guys are trying to go to $100 million in revenue and commensurate valuation in five to seven years. So, if they want to cash out the fact that you’re staying private in 15 years, that means that there is going to be some amount of change in ownership and that’s reasonable.

Do you want to go public or do you want to stay private?

Scaling to $500M in Revenue: ModMed CEO Daniel Cane (Part 6)

Sramana Mitra: That means architecturally, you’re going to put a recording and transcription agent on the iPad, this is not happening on the cloud, right?

Daniel Cane: Right. There are several reasons for this approach. First and foremost, it’s about performance and latency. By keeping everything on the device, we’re minimizing the amount of information leaving the iPad, which enhances security. The application operates transiently, generating a temporary transcript.

Scaling to $500M in Revenue: ModMed CEO Daniel Cane (Part 5)

Sramana Mitra: Double click down for me on the AI aspect. I know you were doing AI right up front, but of course, AI has evolved. The market has evolved. Market’s receptivity to AI has evolved. AI has come of age, so to speak in the last fifteen years. Where are you with AI? What are you doing with AI? What are you seeing in the adoption of AI?

Scaling to $500M in Revenue: ModMed CEO Daniel Cane (Part 2)

Sramana Mitra: Okay. So that’s one positioning differentiation. What about within the private practice market? Why do your customers pick you and what is special about it? What are the needs of a dermatology private practice or an OB-GYN practice or a plastic surgery practice? What’s special about each of these individual types of practices?

Scaling to $500M in Revenue: ModMed CEO Daniel Cane (Part 1)

I first spoke with Dan a decade back. Here is the story. This conversation offers insights on his scaling strategy with ModMed.